

Lyme Neuroborreliosis in Children

Subjects: **Pediatrics**

Contributor: Konrad Kaminiów , Sylwia Kozak

Lyme neuroborreliosis (LNB) is an infectious disease, developing after a tick bite and the dissemination of *Borrelia burgdorferi sensu lato* spirochetes reach the nervous system. The infection occurs in children and adults but with different clinical courses. Adults complain of radicular pain and paresis, while among the pediatric population, the most common manifestations of LNB are facial nerve palsy and/or subacute meningitis.

borreliosis **lyme borreliosis** **neuroborreliosis**

1. Introduction

As *Borrelia* pathogens show the ability to spread easily and affect various tissues in the body, they activate the host's immune defense, causing the multisystem inflammation and symptoms of the disease [1]. As the spirochetes disseminate through the bloodstream, or tissue planes, different manifestations of LB develop. According to The European Federation of Neurologic Societies (EFNS) guidelines, the diagnosis of definite LNB must be based on the fulfillment of three criteria, and two of them for possible LNB: Neuroborreliosis infection manifests itself by facial nerve palsy, meningitis, and radiculopathy; however, symptoms differ in the European and American population due to different spirochete species [1].

The following paper presents the summary of the results of the latest research on **Lyme neuroborreliosis** in children. The collected data were divided into sections, representing various aspects of this disease with emphasis on neurological manifestations, diagnosis, and treatment.

References

References presented the **Lyme neuroborreliosis** (LNB) definitions according to EFNS guidelines [2] (Table 1 and Table 2).

1. Rauer, S.; Kastenbauer, S.; Hofmann, H.; Fingerle, V.; Huppertz, H.-I.; Hunfeld, K.-P.; Krause, A.; Ruf, B.; Dersch, R. Guidelines for Diagnosis and Treatment in Neurology–Lyme Neuroborreliosis. **Table 1.** Criteria for definite and possible Lyme neuroborreliosis (LNB) [2]. *GMS Ger. Med. Sci.* 2020, 18, 18.

2. Mygland, Å.; Ljøstad, U.; Fingerle, V.; Rupprecht, T.; Schmutzhard, E.; Steiner, I. EFNS Definite neuroborreliosis * Neurological symptoms suggestive of LNB *** Guidelines on the Diagnosis and Management of European Lyme Neuroborreliosis: Guidelines on Fulfillment of 3 criteria Neuroborreliosis. *Eur. J. Neurology* 2010, 17, 844 (CSF) pleocytosis

3. Rožič, M.; Lah, J.; Ružič-Sabljic, E.; Kastrin, A.; Arnez, M. Lyme Neuroborreliosis in Children: Possible neuroborreliosis • Intrathecal *Borrelia burgdorferi sensu lato* (Bb) antibody production Etiology and Comparison of Clinical Findings of Lyme Neuroborreliosis Caused by *Borrelia Garinii* and *Borrelia Afzelii*. *Pediatric Infect. Dis. J.* 2019, 38, e279–e284.

4. Crippel, M.; Paris, N.B.; Geert, L.; Investigations on the Mode and Dynamics of Transmission and IgG antibody activity of *Borrelia burgdorferi sensu stricto* and *Borrelia afzelii* in ixodes ricinus ticks. Vector-Borne Zoonotic Dis. 2002, 2, 3–9.

Table 2. Criteria for definite late Lyme neuroborreliosis (LNB) with polyneuropathy [2].

5. Vandenesch, A.; Turbelin, C.; Couturier, F.; Arena, C.; Jaulhac, B.; Ferquel, F.; Choumet, V.; Saugeon, C.; Coffinieres, E.; Blanchon, P.; Prevalence and Hospitalisation Rates of Lyme Borreliosis, France, 2004 to 2012. Eurosurveillance 2014, 19, 20883.
Clinical diagnosis of acrodermatitis chronica atrophicans (ACA)
6. Skogman, B.H.; Croner, S.; Nordwall, M.; Eknefelt, M.; Emerudh, J.; Forsberg, P. Lyme <i>Borrelia burgdorferi sensu lato</i> (Bb)-Specific antibodies in serum
Neuroborreliosis in Children: A Prospective Study of Clinical Features, Prognosis, and Outcome. Pediatric Infect. Dis. J. 2008, 27, 1089–1094.

2. Materials and Methods

7. Gödermark, L.; Sigurdsson, V.; Näs, W.; Wall, P.; Trollfors, B. Neuroborreliosis in Swedish Children: A Population-Based Study on Incidence and Clinical Characteristics. Pediatric Infect. Dis. J. 2017, 36, 1052–1056.

8. Stanek, G.; Wormser, G.P.; Gray, J.; Strle, F. Lyme Borreliosis. Lancet 2012, 379, 461–473.

9. Sykes, R.A.; Makiello, P. An Estimate of Lyme Borreliosis Incidence in Western Europe. J. Public Health 2016, fdw017.

10. Berglund, J.; Eitrem, R.; Ornstein, K.; Lindberg, A.; Ringnér, Å.; Elmrud, H.; Carlsson, M.; Runehagen, A.; Svanborg, C.; Norrby, R. An Epidemiologic Study of Lyme Disease in Southern Sweden. N. Engl. J. Med. 1995, 333, 1319–1324.

3. Results

11. Wilking, H.; Stark, K. Trends in Surveillance Data of Human Lyme Borreliosis from Six Federal

3.1. Etiology and Transmission 2009–2012. Ticks Tick-Borne Dis. 2014, 5, 219–224.

12. Dryden, M.S.; Saeed, K.; Ogborn, S.; Swales, P. Lyme Borreliosis in Southern United Kingdom, Europe, infected Ixodes ricinus is responsible for the transmission of spirochetes and the development of Lyme borreliosis. According to the literature, B. garinii followed by B. afzelii and B. burgdorferi is considered to be the most common etiological agent of neuroborreliosis. However, it needs to be pointed out that the above information applies to adults, as data about the etiological basis of LNB in European children is limited. A study conducted in Slovenia proved to help verify this information, as B. garinii followed by B. afzelii turned out to be dominant in the development of pediatric LNB [3].

13. Skogman, B.H.; Glimmacker, K.; Nordwall, M.; Vrethem, M.; Ödkvist, L.; Forsberg, P. Long-Term Clinical Outcome after Lyme Neuroborreliosis in Childhood. Pediatrics 2012, 130, 262–269.

14. Tveitnes, D.; Nataas, O.B.; Skadberg, Ø.; Øymar, K. Lyme Meningitis, the Major Cause of Childhood Meningitis in an Endemic Area: A Population Based Study Arch. Dis. Child. 2012, 97, 215–220.

15. Stile, P.; Wormser, G.P.; Mead, P.; Dhadduval, K.; Longo, M.V.; Adenikhiju, O.; Soman, S.; Tefera, F.; Mardaspi, V.; Lorne-Fulan, S. Gender Disparity between Cutaneous and Non-Cutaneous Manifestations of Lyme Borreliosis. PLOS ONE 2013, 8, e64110.

16. Guet-Revillet, H.; Levy, C.; Vallet, C.; Maghraoui-Slim, V.; Dommergues, M.-A.; Hentgen, V.; Paget, C.; Laugel, V.; Cohen, R.; Ferroni, A. Lyme Neuroborreliosis in Children: Report of Nine Cases and a Review of the Literature. Arch. Pédiatrie 2019, 26, 133–137.

3.2. Epidemiology

17. Telloch, S.; Semper, A.F.; Brooks, T.; Russell, K.; Halperin, D.; Christley, R.M.; Radford, A.D. [6].
Suburban, Rural, and Urban The Demographic and Geographic Distribution of Laboratory-Confirmed Lyme Disease Cases in England and Wales (2013–2016): An Ecological Study. *BMC Infect. Dis.* 2019, 19, 1028064.
bavariensis (B. burgdorferi sensu stricto (B. burgdorferi)), and very rarely, *Borrelia spielmanii*, *Borrelia bissetii*, *Borrelia lusitaniae*, and *Borrelia valaisiana* are indicated as etiological factors of LB, while in North America, *Borrelia burgdorferi sensu stricto* remains the almost exclusive cause of this disease [3].
2015, 2015, 1–6.

19. Forde, K.; McGuire, J.; Galloway, P.; Dryden, M.; Keady, D.; Hanrahan, B.; McDermott, C.; and others. The Clinical Presentation, Treatment, and Outcome of Lyme Disease in the Republic of Ireland over a 5-Year Period: a Retrospective Cohort Study. *Emerg. Infect. Dis.* 2020.

20. ECDC Comment: European Commission Updates Communicable Disease Surveillance List—The highest incidence of LB occurs in the main endemic areas—Scandinavia and Central Europe—and are estimated for more than 300 cases per 100,000 inhabitants [8], while in Western Europe, there are significantly fewer cases reported [9]. Unfortunately, the above information refers to all manifestations of *Borrelia* infections,

21. Hansen, K.; Kober, A.M. The Clinical and Epidemiological Profile of Lyme Neuroborreliosis is not specific. *Acta Neurol. Scand.* 1995, 91, 100–104.
Denmark 1985–1990: A Prospective Study of 187 Patients with *Borrelia burgdorferi* Specific IgG Intrathecal Antibody Production. *Brain* 1992, 115, 399–423.

22. Oschmann, P.; Dorndorf, W.; Hornig, C.; Schäfer, C.; Wellensiek, H.J.; Pflughaupt, K.W. Stages and Syndromes of Neuroborreliosis. *J. Neurol.* 1998, 245, 262–272.
It was estimated that the highest incidence of LB is bimodal and occurs among adults aged 45–59 years and children (with male predominance [6][13][14][15]) aged 5–9 years, with the peak at 7 years [16][17]. According to a

23. Keiser, R. Variable CSF Findings in Early and Late Lyme Neuroborreliosis: A Follow-up Study of 47 Patients. *J. Neurol.* 1994, 242, 26–36.

24. Koedel, U.; Fingerle, V.; Pfister, H.-W. Lyme Neuroborreliosis—Epidemiology, Diagnosis and Management. *Nat. Rev. Neurol.* 2015, 11, 446–456.
At present, no figures showing the rate of LB or LNB worldwide occurrence are available, and no population-based studies of the incidence and clinical presentation of serologically confirmed [Lyme disease](#) in European children

25. Huppertz, H.; Bahr, M.; Heine, J.; Fingerle, V.; Knebel, M.; Klein, R.; Krenke, G. EU-wide surveillance of Lyme disease: Diagnostic strategies for Lyme Borreliosis in Children and Adolescents: Recommendations by the Committee for Infectious Diseases and Vaccinations of the German Academy of Pediatrics and Adolescent Health. *Eur. J. Pediatrics* 2012, 171, 1619–1624.

3.3. Symptoms
Academy of Pediatrics and Adolescent Health. *Eur. J. Pediatrics* 2012, 171, 1619–1624.

3.3.1. [Lyme Neuroborreliosis Symptoms—General Information](#)
and Literature Review. *Arch. Dis. Child.* 2000, 83, 67–71.

27. Broekhuijsen-van Henten, D.M.; Braun, K.P.; Wolfs, T.F. Clinical Presentation of Childhood Neuroborreliosis; Neurological Examination May Be Normal. *Arch. Dis. Child.* 2010, 95, 910–914.

28. Esposito, S.; Bosis, S.; Sabatini, C.; Tagliaferri, L.; Principi, N. *Borrelia burgdorferi* Infection and Lyme Disease in Children. *Int. J. Infect. Dis.* 2013, 17, e152–e158.

Early LNB	Late LNB
Neurological symptoms existing for <6 months	Neurological symptoms existing for >6 months

3	Early LNB	Late LNB	Lancet
3	PNS manifestations (Bannwarth's syndrome, other peripheral neurological manifestations are plexus neuritis and mononeuritis multiplex)	PNS manifestations (mononeuropathy, radiculopathy and polyneuropathy)	nical Cohort
3	CNS manifestations (confusion, cerebellar ataxia, opsoclonus–myoclonus, ocular flutter, apraxia, hemiparesis or Parkinson-like symptoms)	CNS manifestations (cerebral vasculitis, chronic progressive Lyme encephalitis or encephalomyelitis with tetraspastic syndrome, spastic–ataxic gait disorder and disturbed micturition)	K.; Lee, Northwest of

England. Clin. Infect. Pract. 2020, 6, 100017.
Table 4. General information on the clinical course of early and late neuroborreliosis [1][21][22][23][24][25].
Abbreviations: PNS—peripheral nervous system, CNS—central nervous system.

33. Arnason, S.; Hultcrantz, M.; Nilsson, A.; Laestadius, A. Peripheral Facial Nerve Palsy in Children	Lyme Neuroborreliosis Stage	Early Lyme Neuroborreliosis	Late Lyme Neuroborreliosis (Chronic Lyme Neuroborreliosis)	09,
3	Persistence of symptoms	weeks to months [21][22][23]	months to years [21][22][23]	Case
3	Occurrence	over 91% of cases—patients with neuroborreliosis having early manifestations (a total number of 330 patients) [22]	less than 9% of cases—patients with neuroborreliosis having late manifestations (a total number of 330 patients) [22]	008, operative
3	Neurological symptoms appearance	painful meningopolyradiculitis, unilateral or bilateral facial paresis (Bannwarth's syndrome), cranial neuritis, plexus neuritis, mononeuritis multiplex meningitis in children	encephalomyelitis with spastic atactic gait disturbance bladder dysfunction Isolated meningitis is very rare	ral Bone
3	Characteristic trait/distinguishing feature	radicular pain	rarely any pain	niology . 2009,

39. Lorch, M.; Teach, S.J. Facial Nerve Palsy: Etiology and Approach to Diagnosis and Treatment. Pediatric Emerg. Care 2010, 26, 763–769.

3.3.2. The Clinical Image in Children with Lyme Neuroborreliosis

40. Ciorba, A. Facial Nerve Paralysis in Children. WJCC 2015, 3, 973.

Clinical presentation of **Lyme neuroborreliosis** presents itself differently from weeks to months after exposure. In children, early LNB with a short duration of symptoms is usually distinguished. Small children can additionally present with loss of appetite, fatigue, or changes in mood [2][6][26][27]; however, these symptoms occur along with

42. Backman, K.; Skogman, B.H. Occurrence of Erythema Migrans in Children with Lyme Neuroborreliosis and the Association with Clinical Characteristics and Outcome—A Prospective Cohort Study. BMC Pediatr. 2018, 18, 189.

43. Tveitnes, D.; Øymar, K.; Nataas, O. Laboratory Data in Children with Lyme Neuroborreliosis, Facial nerve palsy next to Lymphocytic meningitis is the most common neurological symptom of Lyme Relation to Clinical Presentation and Duration of Symptoms. Scand. J. Infect. Dis. 2009, 41, 355–362.

neuroborreliosis in the pediatric population (**Figure 1**) [7][10][28][29][30][31]. It needs to be pointed out that clinical manifestations of LNB, comparing to other CNS infections, significantly differ, as they are often characterized by

44. Bordsius P.; Meier, S.; Fingerle, V.; Klier, C.; Hübner, J.; Kern, W. CXCL13 May Improve
e.g. [Diagnosis in Early Neuroborreliosis with Atypical Laboratory Findings](#). BMC Infect Dis. (2012) 12, no
abstr. 5. **Fatalities in mental status; skull, spine and meninges; cranial nerves; motor examination; sensory examination;**

coordination; reflexes; and gait and station) which can also lead to misdiagnosis and delay in proper treatment
45. Dessau, R.B.; van Dam, A.P.; Fingerle, V.; Gray, J.; Hovius, J.W.; Hunfeld, K.-P.; Jaulhac, B.;
implementation

Kahl, O.; Kristoferitsch, W.; Lindgren, P.-E. To Test or Not to Test? Laboratory Support for the
Diagnosis of Lyme Borreliosis: A Position Paper of ESGBOR, the ESCMID Study Group for Lyme
Borreliosis. Clin. Microbiol. Infect. 2018, 24, 118–124.

46. Wilske, B.; Fingerle, V.; Schulte-Spechtel, U. Microbiological and Serological Diagnosis of Lyme
Borreliosis. FEMS Immunol. Med. Microbiol. 2007, 49, 13–21.

47. Dudzińska, M.; Stettner, D. Manifestacje Kliniczne Neuroboreliozy w Materiale Oddziału
Neurologii Dziecięcej w Chorzowie. Neurol. Dziecięca 2011, 20, 27–33.

48. Goettner, G.; Schulte-Spechtel, U.; Hilmann, R.; Liegl, G.; Wilske, B.; Fingerle, V. Improvement
of Lyme Borreliosis Serodiagnosis by a Newly Developed Recombinant Immunoglobulin G (IgG)
and IgM Line-Immunoblot Assay and Addition of VlsE and DbpA Homologues. J. Clin. Microbiol.
2005, 43, 3602–3609.

49. Wilske, B.; Fingerle, V.; Herzer, P.; Hofmann, A.; Lehner, G.; Peters, H.; Pfister, H.W.; Preac-
Mursic, V.; Soutschek, E.; Weber, K. Recombinant Immunoblot in the Serodiagnosis of Lyme
Borreliosis: Comparison with Indirect Immunofluorescence and Enzyme-Linked Immunosorbent
Assay. Med. Microbiol. Immunol. 1993, 182, 255–270.

3.3.3. Facial Nerve Palsy (FNP)

50. Liang, F.T.; Aberer, E.; Cinco, M.; Gern, L.; Hu, C.M.; Lobet, Y.N.; Ruscio, M.; Voet, P.E., Jr.;
Weynants, V.E.; Philipp, M.T. Antigenic Conservation of an Immunodominant Invariable Region of
the VlsE Lipoprotein among European Pathogenic Genospecies of Borrelia burgdorferi SL. J.
Infect. Dis. 2000, 182, 1455–1462.

51. Aguero-Rosenfeld, M.E.; Wang, G.; Schwartz, Jr., Wormser, G.P. Diagnosis of Lyme Borreliosis.
CMR 2005, 18, 484–509.

52. Ornstein, K.; Berglund, J.; Bergström, S.; Norrby, R.; Barbour, A.G. Three Major Lyme Borrelia
Genospecies (Borrelia burgdorferi Sensu Stricto, B. Afzelii and B. Garinii) Identified by PCR in
Cerebrospinal Fluid from Patients with Neuroborreliosis in Sweden. Scand. J. Infect. Dis. 2002,
34, 341–346.

53. Skogman, B.H.; Wilhelmsson, P.; Atallah, S.; Petersson, A.C.; Ornstein, K.; Lindgren, P.-E. Lyme
Neuroborreliosis in Swedish Children—PCR as a Complementary Diagnostic Method for
Detection of Borrelia burgdorferi Sensu Lato in Cerebrospinal Fluid. Eur. J. Clin. Microbiol. Infect.
2010, 39, 100–106.

3.3.4. Severity and Duration of FNP

54. Coyle, P.K.; Schutzer, S.E. Neurologic Aspects of Lyme Disease. Med. Clin. 2002, 86, 261–284.
A study of 98 children with LNB presenting with facial nerve palsy at admission indicated that the severity of facial
nerve dysfunction (The House Brackman grading system) was described most frequently as moderate (19%), and

55. Weitzel, T.; Bergmann, S.; Jöckel, S.; Zenz, W.; Daghöfer, F.; Krawinkel, J.; Klein, G.; Albrecht, E. CXCL13 Chemokine in Pediatric and Adult Neuroborreliosis. *Acta Neurol Scand* 2011, 124, 321–328. [CrossRef]

56. Remy, M.M.; Schöbl, N.; Kottanattu, L.; Pfister, S.; Duppenhaler, A.; Suter-Riniker, F. Cerebrospinal Fluid CXCL13 as a Diagnostic Marker of Neuroborreliosis in Children: A Retrospective Case-Control Study. *J. Neuroinflamm.* 2017, 14, 1–9.

3.3.5. Lumbar Puncture

57. Henningsson, A.J.; Lager, M.; Brännström, R.; Tjernberg, I.; Skogman, B.H. The Chemokine CXCL13 in Cerebrospinal Fluid in Children with Lyme Neuroborreliosis. *Eur. J. Clin. Microbiol. Infect. Dis.* 2018, 37, 1983–1991.

58. Krawczuk, K.; Czupryna, P.; Pancewicz, S.; Oldak, E.; Król, M.; Moniuszko-Malinowska, A. Comparison of Neuroborreliosis Between Children and Adults. *Pediatric Infect. Dis. J.* 2020, 39, 7–11.

59. Kah, L.; Seod, S.R.; Maytal, J. Pseudotumor Cerebri in Lyme Disease: A Case Report and Literature Review. *Pediatric Neurol.* 1998, 18, 439–441.

3.3.6. Differential Diagnosis of Facial Nerve Palsy

60. Bauer, S.; Kastenbauer, S.; Fingerle, V.; Hunfeld, K.-P.; Huppertz, H.-I.; Dersch, R. Lyme Neuroborreliosis. *Dtsch. Ärzteblatt Int.* 2018, 115, 751.

61. National Institute for Health and Care Excellence (Great Britain); National Guideline Centre (Great Britain). Lyme Disease: Diagnosis and Management; National Institute for Health and Care Excellence: London, UK, 2018.

62. Goetze, S.; Hienicke, C.; Elsner, P. Phototoxicity of Doxycycline: A Systematic Review. *Clinical Manifestations, Frequency, Co-factors, and Prevention.* *Skin Pharm. Physiol.* 2017, 30, 76–80.

Table 5. Possible causes of acquired facial nerve palsy in children [39][40][41].

Etiology	Infectious	Inflammatory	Neoplastic	Traumatic	vasc.
Symptoms	Ramsay Hunt Syndrome				
	Epstein-Barr virus				
	Haemophilus influenzae		Schwannomas of the VII c.n.		
	Tuberculosis				
	Lyme disease				
	Cytomegalovirus	Henoch-Schönlein purpura	Hemangiomas	Temporal bone fracture	
	Adenovirus		Rhabdomyosarcoma	iatrogenic	
	Rubella	Kawasaki syndrome	Temporal bone histiocytosis		
	Mumps		Leukemia		
	Mycoplasma pneumonia		Parotid gland tumors		
	Human immunodeficiency virus				
	Acute otitis media				

3.3.7. The Occurrence of Erythema Migrans in Children with Lyme Neuroborreliosis

67. Cairns, V.; Garwin, J. Post-Lyme Borreliosis Syndrome: A Meta-Analysis of Reported Symptoms. *Epidemiol. Infect.* 2005, **134**, 1340–1345. In 94% of cases, it was an ipsilateral type of FNP [42]. It was also

68. Halperin, J.J.; Shapiro, E.D.; Logigian, E.; Belman, A.L.; Dotevall, L.; Wormser, G.P.; Krupp, L.; cases. Additionally, the majority of patients with EM had the diagnosis of LNB evaluated in a shorter period of time.

69. Gronseth, G.; Bever, C.T. Practice Parameter: Treatment of Nervous System Lyme Disease (an Evidence-Based Review): Report of the Quality Standards Subcommittee of the American

3.3.8. Lyme Meningitis

Lyme meningitis in children with neuroborreliosis can be easily overlooked due to very mild symptoms. However, the course of the disease is different when cranial nerve deficits occur. A Systematic Review. *J. Evid.-Based Med.* 2017, **10**, 177–188.

Retrieved from <https://encyclopedia.pub/entry/history/show/27681>

The data collected indicate isolated meningitis (without radicular symptoms) as most common among children [10] [21] [24] [30]. In every case of LNB, the following changes in CSF can be observed: pleocytosis, disruption of the blood–CSF barrier, and intrathecal immunoglobulin synthesis [1]. However, in the very early stages of LNB, the CSF parameters can be normal [43]. The research of Stanek G. et al. shows that pleocytosis with WBC ≥ 7 and $> 90\%$ mononuclear cells in CSF are features characteristic of pediatric neuroborreliosis [8].

Lyme meningitis can overlap with the viral one, but it is possible to distinguish them, as symptoms of LNB are of less acute onset. Further research showed that neuroborreliosis was the most common causative agent of meningitis in children aged 5–9 years, while Haemophilus influenzae type b, pneumococci, and meningococci caused much lower incidence [7]. That fact should raise awareness and support the consideration of [Lyme neuroborreliosis](#) as a childhood disease.

3.3.9. The Comparison of the Clinical Image Caused by *Borrelia garinii* and *Borrelia afzelii*

The frequency of various clinical presentations in children with [Lyme neuroborreliosis](#) depends on the etiological agent and is different when caused by *Borrelia garinii* and *Borrelia afzelii* (Figure 2) [32]. The original study conducted in Slovenia reported significant insights of *B. garinii* clinical image being more often not suggestive of CNS involvement but more pronounced CNS inflammation than in *B. afzelii* infection [3].




Figure 2. Presentation of the symptoms in children with Lyme neuroborreliosis caused by *Borrelia garinii* and *Borrelia afzelii* [32].

3.4. Diagnostic Process

When assessing patients for [Lyme neuroborreliosis](#), the following factors should be taken into consideration: specific clinical symptoms of LNB, the likelihood of the patient's exposure to infected ticks, the possibility of other illnesses with similar symptoms, and lastly, the results of serological and sometimes other diagnostic tests. In many cases, the currently used laboratory techniques have only limited possibilities to differentiate between previous and active *Borrelia* infection. The history and physical examination are, therefore, of decisive importance.

3.4.1. The Laboratory Diagnostics of CSF

A lumbar puncture is performed in the majority of cases when NB in a child is suspected. The limitation of the LP procedure is associated with the lack of parental consent, not rarely noted in the literature. Inflammatory CSF changes include pleocytosis with the lymphocytes predominance, blood–CSF barrier dysfunction and intrathecal immunoglobulin synthesis, with the exception in the very early stage [1]. Attention should be also paid to elevated [protein](#) levels, while glucose is within the normal range [6]. The early stage of the disease among immunocompromised patients or NB caused by the etiological agent of *B. afzelii* are considered to be the reasons for such normal CSF results [44].

It is also worth paying attention to the research of Rožič, Mojca MD et al. who showed CSF findings in Slovenian children according to different etiological agents causing LNB [3].

3.4.2. Intrathecal Antibody Production

When the serological examination for [Lyme disease](#) is positive or when there is a strong suspicion of neuroborreliosis in the absence of antibodies in the blood, the cerebrospinal fluid is examined, and intrathecal (non-*Borrelia*-specific IgM) antibody production is assessed. The detection of intrathecal synthesis of antibodies against *B. burgdorferi*, indicated as a gold standard, confirms the diagnosis of definite LNB [25]. For the determination of intrathecal antibody production, a sample for the determination of antibodies in the blood on the day of CSF collection is taken. The diagnostic sensitivity is estimated in approximately 80% of children presenting with clinical manifestations of LNB for less than 6 weeks and increases with the duration of the symptoms [45].

3.4.3. Antibodies in the Serum

ELISA (screening test) and Western blot (confirmation test) are the two-stage basic diagnostic procedures used for the detection of antibodies in the serum [46]. When there is a negative serum serological test result and the LNB is still considered a potential cause of clinical manifestations, the antibody testing should be done 2–4 weeks later in anticipation of seroconversion.

3.4.4. Relevant *Borrelia* Antigens

There is a large number of *B. burgdorferi* diagnostically relevant antigens (**Table 6**), which depend on the stage of the disease. The immunoblot technique allows to separate them, and the knowledge about their occurrence helps to interpret correctly the serological test results.

Table 6. Immunologically relevant *Borrelia* antigens ^{[1][47]}.

Early Immune Response (Mainly IgM) ^{[48][49][50]}	Late Immune Response (Mainly IgG) ^[49]
Flagellar protein, OspC, VlsE	P83/100, p58, p43, p39, p30, p21, DbpA (Osp17), p14, VlsE

3.4.5. *B. burgdorferi* Bacterial Culture Growth

Borrelia cultivation from CSF is not recommended and not widely used as a routine procedure, due to many culturing requirements. The bacteria need to be grown in specific liquid culture media or on the Barbour–Stoenner–Kelly (BSK) medium at 30–34 °C but its sensitivity is suboptimal, ranging from 10% to 30%, which limits its use in clinical practice ^{[2][46][51]}. Additionally, the culturing is a time-consuming (2–3 months) ^[29] process, and there is a need for specialized microbiological laboratories ^[2].

3.4.6. Polymerase Chain Reaction (PCR)

Polymerase chain reaction (PCR) may be used for detection of the *Borrelia* genome in cerebrospinal fluid (CFS) to aid in the diagnosis of recent neuroborreliosis with a short duration of neurological symptoms ^[52].

Due to the small number of copies of the spirochete in samples, the sensitivity of the PCR-based test is low with a sensitivity of 5% ^[53], and can be even lower in the case of late LNB, as spirochetes easily migrate to various CNS tissues ^{[2][54]}; therefore, a negative PCR result does not exclude [Lyme neuroborreliosis](#). For this reason, the PCR test alone is not definitive in the diagnosis of LN disease. Determination of antibody synthesis is always a more sensitive alternative in late neuroborreliosis and is usually more sensitive in early neuroborreliosis as well. The specificity of this detection technique is theoretically close to 100% ^[53] and therefore, the detection of *Borrelia* DNA in CSF is evidence of Lyme disease.

3.4.7. Chemokine CXCL13

Determination of CXCL13 in CSF appears to be a promising additional parameter for the diagnosis of early neuroborreliosis in addition to antibody determination, especially in cases where the antibody response is still negative and general parameters, such as pleocytosis and the albumin ratio, provide insufficient definitions for the diagnosis of neuroborreliosis ^{[44][55][56]}. However, there are also significantly lower values of sensitivity of CXCL13 in CSF and are pre-treated with antibiotics before CSF sampling ^[56]. It is not yet clear whether the parameter also has value in late neuroborreliosis. However, CXCL13 cannot be used as a predictive marker for recovery, as research has shown its low concentration on admission among children, who later reported persistent symptom occurrence at the 2-month follow-up ^[57].

3.4.8. Magnetic Resonance Imaging (MRI)

In patients with neuroborreliosis, imaging such as CT scans and MRI of the brain or spinal cord may show focal abnormalities. The comparable abnormalities, such as enhancement of meninges, enhancement of cranial nerves, vasculitis, ischemic foci, or diffuse CNS parenchymal involvement, are also found in other conditions, so the imaging techniques mentioned have no diagnostic value in establishing a diagnosis of Lyme neuroborreliosis [58]. However, clinicians must heighten their awareness of pseudotumor-like picture occurrence in MRI, including visual obscurations and visual loss among children with Lyme meningitis [59].

3.5. Treatment

Neuroborreliosis is a disease that can be effectively treated by antibiotics. However, the implementation of the medications must be preceded by an LNB diagnosis, which in the pediatric population is often delayed or overlooked due to non-specific symptom occurrence. Based on numerous publications, data collected on the treatment of Lyme neuroborreliosis in children are still insufficient or of low quality. Moreover, studies focused on that aspect were conducted even several decades ago, which cannot be accepted in relation to the current clinical research standards.

Despite the existence of many different recommendations on how to treat neuroborreliosis in children, the most important factor is an individual approach to the patient; however, each treatment regimen should be based on clinical evidence. The clinician’s attention must be paid to the patient’s age, allergies, pregnancy, tolerability or other diseases occurrence, etc., to choose the most effective treatment option. However, a dose of antibiotics, the frequency of its application, route of administration, and duration of treatment remain under discussion. The last of the mentioned factors seems to be particularly important nowadays, as unreasonable extended antibiotic courses may result in a growing problem of multidrug-resistant bacteria.

3.5.1. The Antibiotic Treatment Recommendations of Lyme Neuroborreliosis

Although there are different guidelines for treating [Lyme neuroborreliosis](#) (Table 7, Table 8, Table 9 and Table 10) , all recommendations are based on the use of antibiotics characterized by good penetration into the CNS. The treatment should be initiated in all patients with neurological manifestations typical of LNB, inflammatory CSF changes, and positive Borreliaserology, while in cases of possible LNB, antibiotics can only be considered after a differential diagnosis, excluding other diseases.

Table 7. Overview of antibiotic treatment according to guidelines for diagnosis and treatment in neurology—Lyme neuroborreliosis [60].

Antibiotic	Pediatric Dose (Dose/kg × Day)	Duration (Days)
Early Lyme neuroborreliosis		
Ceftriaxone	50 mg	14

Antibiotic	Pediatric Dose (Dose/kg × Day)	Duration (Days)
Cefatoxime	100 mg	14
Penicillin-G	200–500,000 IU	14
Doxycycline	Age 9 and up, 4 mg (maximum 200 mg)	14
Late Lyme neuroborreliosis		
Ceftriaxone	50 mg	14–21
Cefatoxime	100 mg	14–21
Penicillin-G	200–500,000 IU	14–21
Doxycycline	Age 9 and up, 4 mg (maximum 200 mg)	14–21

Table 8. Overview of antibiotic treatment according to National Institute for Health and Care Excellence (NICE) guideline for children aged 9–12 [\[61\]](#).

Children Aged 9–12		
Antibiotics	Dosage	Duration (Days)
Lyme disease affecting the cranial nerves or peripheral nervous system		
Doxycycline (oral) (children under 45kg)	5 mg/kg in 2 divided doses on day 1 followed by 2.5 mg/kg daily in 1 or 2 divided doses For severe infections, up to 5 mg/kg daily	21
Amoxicillin (oral) (children under 33 kg)	30 mg/kg 3 times per day	21
Lyme disease affecting the central nervous system		
Ceftriaxone (intravenous) (children under 50 kg)	80 mg/kg (up to 4 g) once per day	21
Doxycycline (oral) (children under 45 kg)	5 mg/kg in 2 divided doses on day 1 followed by 2.5 mg/kg daily in 1 or 2 divided doses For severe infections, up to 5 mg/kg daily	21
Lyme disease arthritis and acrodermatitis chronica atrophicans		
Doxycycline (oral) (children under 45 kg)	5 mg/kg in 2 divided doses on day 1 followed by 2.5 mg/kg daily in 1 or 2 divided doses	28

Children Aged 9–12		
Antibiotics	Dosage	Duration (Days)
For severe infections, up to 5 mg/kg daily		
Amoxicillin (oral) (children under 33 kg)	30 mg/kg 3 times per day	28
Ceftriaxone (intravenous) (children under 50 kg)	80 mg/kg (up to 2 g) once per day	28
Lyme carditis B		
Doxycycline (oral) (children under 45 kg)	5 mg/kg in 2 divided doses on day 1 followed by 2.5 mg/kg daily in 1 or 2 divided doses	21
Ceftriaxone (intravenous) (children under 50 kg)	80 mg/kg (up to 2 g) once per day	21
Children Under 9 Years		
Antibiotics	Dosage	Duration (Days)
B For hemodynamically unstable Lyme carditis, intravenous ceftriaxone should be used as first choice. Lyme disease affecting the cranial nerves or peripheral nervous system		
Amoxicillin (oral) (children under 33 kg)	30 mg/kg 3 times per day	21
Lyme disease affecting the central nervous system		
Ceftriaxone (intravenous) (children under 50 kg)	80 mg/kg (up to 4 g) once per day	21
Lyme disease arthritis and acrodermatitis chronica atrophicans		
Amoxicillin (oral) (children under 33 kg)	30 mg/kg 3 times per day	28
Ceftriaxone (intravenous) (children under 50 kg)	80 mg/kg (up to 2 g) once per day	28
Lyme carditis (both hemodynamically stable and unstable)		
Ceftriaxone (intravenous) (children under 50 kg)	80 mg/kg (up to 2 g) once per day	21

Table 10. Overview of antibiotic treatment according to National Institute for Health and Care Excellence (NICE) guideline for children aged 12 and over [\[61\]](#).

Children Aged 12 and Over		
Antibiotics	Dosage	Duration (Days)
Lyme disease affecting the cranial nerves or peripheral nervous system		
Doxycycline (oral)	100 mg twice per day or 200 mg once per day	21
Amoxicillin (oral)	1 g 3 times per day	21

Children Aged 12 and Over		
Antibiotics	Dosage	Duration (Days)
Lyme disease affecting the central nervous system		
Ceftriaxone (intravenous) A	2 g twice per day or 4 g once per day	21
Doxycycline (oral)	200 mg twice per day or 400 mg once per day	21
Lyme disease affecting the central nervous system		
Doxycycline (oral)	100 mg twice per day or 200 mg once per day	28
Amoxicillin (oral)	1 g 3 times per day	28
Ceftriaxone (intravenous)	2 g once per day	28
Lyme carditis B		
Doxycycline (oral)	100 mg twice per day or 200 mg once per day	21
Ceftriaxone (intravenous) C	2 g once per day	21

A When an oral switch is being considered, use doxycycline; B Hemodynamically unstable; C Do not use azithromycin to treat people with cardiac abnormalities associated with Lyme disease because of its effect on QT interval

3.5.2. Restrictions on the Use of Doxycycline

The implementation of doxycycline remains contraindicated in children under 8 years, as it may cause teeth staining and enamel hypoplasia due to incomplete dental enamel formation. However, some data indicate that this undesirable effect can be prevented by avoiding sunlight. Some authors even put forward the conclusion that the risk of side effects appearance after short-term use of doxycycline remains minimal, and the potential benefits of using this drug outweigh this risk [62]. Nevertheless, a different alternative antibiotic should be chosen in this age group.

3.5.3. The Antibiotics Treatment Side Effects

All the antibiotics recommended for the treatment of LNB are considered effective and safe, and serious side effects were reported very rarely. Table 11 presents the possible side effects and was created only based on very limited data, but it may raise the awareness of doctors implementing the treatment to their patients.

Table 11. Unfavorable clinical courses under various antibiotics treatment [1][7][61].

Antibiotic	Side Effect
Doxocycline (in children under 8 years)	Teeth staining and enamel hypoplasia
	Vomiting

Antibiotic	Side Effect
Penicillin G	Moderate allergic skin reaction
	Increase in liver enzymes
Ceftriaxone	Asymptomatic gallbladder concrements
Azithromycin	QT interval prolongation
Any	Jarisch–Herxheimer reaction

3.5.4. Non-Antibiotic Treatment of Lyme Neuroborreliosis

According to different studies, steroids are listed among the medications used to treat [Lyme disease](#) ^{[63][64][65]}; however, the current data about steroids implementation with antibiotics or itself are still limited, especially in the pediatric group. The use of steroids requires special attention in patients with peripheral paralysis of nerve VII. As this controversial way of treatment is still under debate among clinicians and there is a lack of randomized controlled trials, steroids remain not recommended. The authors also emphasize the very high rate (95%) of spontaneous remission in children, which also speaks in favor of not using glucocorticoid therapy in the pediatric group of patients.

3.5.5. Treatment Monitoring and Clinical Outcome

The effectiveness of the treatment can be assessed by the clinical manifestations.

Pediatric patients presenting with facial nerve palsy caused by neuroborreliosis recovered faster than those with FNF of different etiology; moreover, the recovery time was observed to be shorter among younger children (aged 0–8 years). It was also stated that after 12 weeks, the overall complete recovery was observed in more than 97% of cases and the rate of recovery did not depend on etiology or age.

The study of 618 children with [Lyme neuroborreliosis](#) showed complete recovery in 29% of the patients by the end of the treatment, and in 63% after 4–6 weeks ^[7].

In general, the clinical outcome is significantly better in children than in adults. Among the pediatric population, the neuropsychological prognosis is favorable and long-term neuropsychologic disorders are not seen in the pediatric population, compared to adults struggling with cognitive disorders and persistent or recurrent neurologic symptoms ^{[66][67][68]}. Moreover, in 11/16 of these children, sequelae were the residua of facial palsy. In the other five, these were residua of other, more severe deficits in acute disease.

4. Conclusions

[Lyme neuroborreliosis](#) in children is considered an uncommon disease, but many reasons may hide the true scale of this problem. The lack of registration of incidence among children, particularly in areas according to specific criteria, in the past and the lack of population-based studies among children make neuroborreliosis disease an excellent field for research.

Undeniably, the diagnosis of [Lyme disease](#) among children is challenging, requiring great knowledge and perceptiveness from clinicians. Due to the multitude of non-specific symptoms, it is easy to misdiagnose and delay the proper treatment. Statistically, most children with symptoms suggesting neuroborreliosis are admitted to primary health care and the general practitioner plays a key role in the diagnosis of a patient with [Lyme disease](#) ^[32]. Of great importance is also increasing the awareness of all health professionals, which can result in fast diagnosis and implementation of appropriate treatment.

It needs to be pointed out that due to global warming, the incidence of LNB will be ever increasing, posing a serious public health problem. There are several steps to achieve better disease control. It is, therefore, extremely important to educate the general society about preventive strategies and alarming symptoms, especially in endemic areas ^[69].